Plasma Levels of MK0633 in Children Ages 6-12 (0633-023)

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the safety, tolerability and plasma levels of single oral doses of MK0633 in pediatric asthma patients ages 6 to less than 12 years.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Patient has mild to moderate asthma

• Patient is able to swallow pills

• Patient is able to have have blood draws

Exclusion Criteria:

• Patient has required a visit to the hospital or emergency room due to an asthmatic event in the last 3 months

• Patient has an upper respiratory tract infection (URI)

• Patient has a history of stroke

• Patient consumes more than 4 caffeinated beverages per day